$4.13
1.47% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$4.13
-1.47 26.25% 1M
-6.87 62.45% 6M
-1.99 32.52% YTD
-0.79 16.06% 1Y
-78.91 95.03% 3Y
-27.13 86.79% 5Y
-116.35 96.57% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 1.47%
ISIN
US45773H2013
Symbol
INO
Sector

Key metrics

Market capitalization $107.79m
Enterprise Value $35.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 177.20
P/S ratio (TTM) P/S ratio 538.95
P/B ratio (TTM) P/B ratio 1.46
Revenue growth (TTM) Revenue growth -76.18%
Revenue (TTM) Revenue $200.00k
EBIT (operating result TTM) EBIT $-119.42m
Free Cash Flow (TTM) Free Cash Flow $-111.18m
Cash position $84.80m
EPS (TTM) EPS $-4.48
P/E forward negative
P/S forward 615.36
EV/Sales forward 202.32
Short interest 13.59%
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.20 0.20
76% 76%
100%
- Direct Costs 2.53 2.53
46% 46%
1,265%
-2.33 -2.33
39% 39%
-1,165%
- Selling and Administrative Expenses 35 35
18% 18%
17,290%
- Research and Development Expense 80 80
28% 28%
39,995%
-117 -117
26% 26%
-58,445%
- Depreciation and Amortization 2.53 2.53
46% 46%
1,265%
EBIT (Operating Income) EBIT -119 -119
26% 26%
-59,712%
Net Profit -113 -113
31% 31%
-56,440%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
11 days ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Lian...
Neutral
PRNewsWire
12 days ago
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences  Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and corresp...
Neutral
PRNewsWire
13 days ago
New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data ...
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 122
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today